ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
Dow Jones
39.069,59
0,01%
Euro vs US Dollar
1,0848
0,00%
Bitcoin
69.181,61
-0,13%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Spyre Therapeutics Inc (SYRE)

  7. Spyre Therapeutics Inc (SYRE) News

SYRE Spyre Therapeutics Inc

32,98
0,30 (0,92%)
25 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Spyre Therapeutics Inc SYRE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,30 0,92% 32,98 06:00:01
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
32,68 32,10 34,00 32,98 32,68
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.5.202422:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
15.5.202413:40EDGAR2Form 8-K - Current report
15.5.202413:30PRNUSSpyre Therapeutics Appoints Accomplished Biopharma Leader..
09.5.202422:11EDGAR2Form 8-K - Current report
09.5.202422:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.5.202422:02PRNUSSpyre Therapeutics Reports First Quarter 2024 Financial..
03.5.202423:00PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
01.4.202423:00PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
18.3.202413:00PRNUSSpyre Therapeutics Announces $180 Million Private Placement
05.3.202423:15EDGAR2Form POS AM - Post-Effective amendments for registration..
01.3.202423:25PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
01.3.202412:14EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
29.2.202423:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
29.2.202422:14EDGAR2Form 8-K - Current report
29.2.202422:05PRNUSSpyre Therapeutics Reports Fourth Quarter and Full Year 2023..
26.2.202413:30PRNUSSpyre Therapeutics to Participate in the 44th Annual TD..
21.2.202403:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202402:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202421:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202400:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202422:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202413:30PRNUSSpyre Therapeutics Announces Three Abstracts Accepted for..
05.2.202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202423:25EDGAR2Form 3 - Initial statement of beneficial ownership of..
05.2.202413:36EDGAR2Form 8-K - Current report
05.2.202413:30PRNUSSpyre Therapeutics Appoints Accomplished Biopharma and IBD..
03.2.202402:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.2.202402:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.2.202423:30PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
18.1.202422:26EDGAR2Form 8-K - Current report
29.12.202323:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29.12.202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202303:56EDGAR2Form D - Notice of Exempt Offering of Securities
23.12.202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202323:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
22.12.202323:00PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
22.12.202322:32EDGAR2Form S-1 - General form for registration of securities under..
11.12.202323:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.12.202323:21EDGAR2Form SC 13D/A - General statement of acquisition of..
08.12.202322:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
08.12.202314:45EDGAR2Form 8-K - Current report
08.12.202300:20PRNUSSpyre Therapeutics Announces $180 Million Private Placement

Kürzlich von Ihnen besucht

NASDAQ
SYRE
Spyre Therapeutics
USOTC
LCHTF
Livechat Software (CE)
COIN
HYCONETH
BIT
P1YS93
NLBNPIT1YS93 20351221 27...
TSXV
SGU
Signature Resources
POLO
BLKBTC
BlackCoin
USOTC
LTSSF
Lotus Bakeries NV (PK)
EU
FR2CIBFS4906
Credit Agricole CIB FCIA...
BIT
P1XRT7
NLBNPIT1XRT7 20991231 1....
LATK
XPRUSDT
Proton
GATE
MBLETH
MovieBloc
COIN
KOLINGBP
BIT
UV8C6P
UniCredit Bank
EU
P915S
P915S
BITMOT
891585
Ifc Zc Mg30 Brl
NYSE
CYNI
CYAN INC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten